TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02467023
Drug: Muscle Biopsy Medication: Fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to starting the muscle biopsy, you can receive a drug, Fentanyl, to make you more comfortable during the procedure. 50-100 micrograms of Fentanyl will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
Study: NCT03652051
Drug: AZR-MD-001 Mid Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZR-MD-001 is an ophthalmic ointment
Study: NCT03652051
Drug: AZR-MD-001 Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZR-MD-001 is a vehicle ophthalmic ointment
Study: NCT01823770
Drug: Placebo patchs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject randomized on the placebo group will be treated with placebo patchs, following the same modalities and study periods that the rotigotine arm
Study: NCT01972854
Drug: placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0% riboflavin ophthalmic solution
Study: NCT02008773
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules 6/day oral for 16 weeks
Study: NCT02374567
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02374567
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02374567
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00794690
Drug: Cimicifuga racemosa extract for the group
Normalized name: Cimicifuga racemosa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of Cimicifuga racemosa extract daily dor 12 months
Study: NCT04712357
Drug: Vitamin C 500 MG Oral Tablet
Normalized name: vitamin C 500 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 500 MG per day for 10 days
Study: NCT02374567
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02166268
Drug: AVANZ Phleum pratense 15,000 SQ+
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02166268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04643795
Drug: MGL-3196
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral dose for 6 days
Study: NCT01566201
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: water for injection
Study: NCT04602442
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
Study: NCT00400439
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po daily for 24 weeks
Study: NCT01267942
Drug: Enhancin
Normalized name: IgA enhancing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.~Oral dose of the same at the same dosage for the active comparator arm.
Study: NCT03520907
Drug: Ilioinguinal/iliohypogastric Nerve Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: block will be performed under real-time ultrasound guidance
Study: NCT02783092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be an oral solution of corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
Study: NCT01737853
Drug: Ganforti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
Study: NCT01737853
Drug: Krytantek
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
Study: NCT01474720
Drug: Zostavax vaccine
Normalized name: ZOSTAVAX VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
Study: NCT03424356
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1mcg/kg for induction
Study: NCT04680429
Drug: RP7214
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single and multiple ascending doses of RP7214
Study: NCT04680429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single and multiple ascending doses of matching placebo
Study: NCT00527982
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg by mouth daily for a total of 12 months.
Study: NCT00789672
Drug: levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
Study: NCT00789672
Drug: levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
Study: NCT00450645
Drug: low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH were continued for additional 6 months after detection of residual vein thrombosis (6 months after the index deep vein thrombosis) in patients randomized to group A. LMWH are stopped in patients randomized to group B or in those patients without residual vein thrombosis after 6 months from the index DVT. Dosage of LMWH are 75% of the therapeutic dosage (almost 1 mg/Kg every 12 hours)
Study: NCT00680797
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel
Study: NCT00854035
Drug: MK-0431/ONO-5435
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind period (16 wk); 50 mg QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50mg QD to 100mg QD
Study: NCT00854035
Drug: MK-0431/ONO-5435
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind period (16 wk); placebo QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Study: NCT04302415
Drug: There is no other intervention, only clinical treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: There is no other intervention, only clinical treatment.
Study: NCT00639756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given for 2 weeks
Study: NCT01936844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for days 1, 2, and 3
Study: NCT01838590
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Study: NCT00305604
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin matching placebo for up to a 24-wk treatment period.
Study: NCT04565600
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 Mg Oral Tablet
Study: NCT04228601
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRINOX
Study: NCT03400163
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo QD
Study: NCT02790710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03147443
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
Study: NCT03147443
Drug: Tested drug minus heat-clearing herbs
Normalized name: Arctium minus root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is the decoction of the Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
Study: NCT00715858
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule, 100 mg, b.i.d., 12 months
Study: NCT00715858
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matched to rifampin; placebo matched to doxycycline
Study: NCT03489512
Drug: A (Chloraprep)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloraprep will be used for the insertion and maintenance of the intravascular device while it is in use (Chlorhexidine 2% + alcohol 70%)
Study: NCT03489512
Drug: B (Clorhexidine 2%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous clorhexidine (2%) will be used for the insertion and maintenance of the intravascular device while it is in use
Study: NCT01007721
Drug: 671800 ED placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules of BI 671800 ED placebo (bid in the morning and evening)
Study: NCT04019769
Drug: L-glutamine
Normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: product will be obtained by Endari and administered by NIH pharmacy. Patient will take supplement as prescribed
Study: NCT03043729
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 350 mg/m\^2 i.v. as 2h infusion on Day 1 (Arm A + Arm B)
Study: NCT01313208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection
Study: NCT03615066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally every 7 days for 24 doses in fasted state
Study: NCT03615066
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily with food
Study: NCT00109577
Drug: MCN36 (nutritional supplement)
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: nutritional supplement
Study: NCT00109577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: nutritional supplement
Study: NCT00089947
Drug: Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02034734
Drug: ASP3652
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04969679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
Study: NCT00982202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 3 tablets daily for \~18 months
Study: NCT00520260
Drug: bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.09%, BID, 6 weeks
Study: NCT00520260
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4%, BID, 6 weeks
Study: NCT02461888
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT00754130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets before every meal (q.a.c) Treatment period is 5 days.
Study: NCT00754130
Drug: MK-0941
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.
Study: NCT00808210
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral or parenteral repeating dose
Study: NCT00808210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT01376999
Drug: FSH-r (Follicule stimulate hormone)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-Up: 75 IU FSH-r Step-Down: 150 FSH-r
Study: NCT01846650
Drug: Capecitabine tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral Capecitabine tablets 2000mg qd
Study: NCT04421209
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets administered with the same schedule of Propranolol tablets
Study: NCT01192828
Drug: taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Take Taurine for 4 1/2 days, two doses per day
Study: NCT00119496
Drug: theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral theophylline, 200mg bd
Study: NCT00119496
Drug: inhaled beclomethasone and oral theophylline
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)
Study: NCT00820222
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
Study: NCT03327558
Drug: Apriso 0.375G ER CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER capsule
Study: NCT01300260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT00377364
Drug: Drug: Acetaminophen, Drug: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
Study: NCT03903939
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuously infusion for 72 hours equal volume to Iloprost
Study: NCT00095173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusions, IV, N/A, every 4 weeks, 6 months.
Study: NCT01424280
Drug: 1440115
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of either 750 mg or 500 mg administered as 250 mg tablets.
Study: NCT01424280
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of matching placebo tablets
Study: NCT02048488
Drug: TSR-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of cycles until progression or unacceptable toxicity develops.
Study: NCT02199964
Drug: Endura, Refresh artificial tears
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over the counter therapy for dry eye, used 4 times a day
Study: NCT01664637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One oval-shaped, opaque-white, hard gelatin capsule of placebo indistinguishable from active drug will be taken orally three times a day for 12 weeks
Study: NCT00799890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-4 capsules
Study: NCT01069705
Drug: Tobramycin inhalation powder
Normalized name: Tobramycin Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin dry powder for inhalation in capsules administered by the T-326 inhaler.
Study: NCT02418884
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.
Study: NCT00187889
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone 25 mg (1 pill) daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
Study: NCT00187889
Drug: Placebo or sugar pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo blinded as 25 mg tablet(1 pill) once daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
Study: NCT02301169
Drug: Administration of placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: This treatment is given as add on therapy to patients' regular analgesic
Study: NCT00218023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.
Study: NCT01032499
Drug: oxytetracycline, taro elixir
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of treatment efficacy between oxytetracycline and taro elixir
Study: NCT01032499
Drug: Taro Elixir
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
Study: NCT02655614
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg tablet or solution of caffeine orally
Study: NCT02249182
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV/SOF FDC administered orally once daily
Study: NCT01769820
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04328272
Drug: Azithromycin 500Mg Oral Tablet
Normalized name: Azithromycin 500mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin administered orally with water
Study: NCT00697710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT01656668
Drug: BC1036
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00075556
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01796821
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day.
Study: NCT01796821
Drug: SR-T100 gel with 1.0 % SM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day.
Study: NCT01796821
Drug: SR-T100 gel with 2.3% SM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application \<1,500 mg gel per day.
Study: NCT02113332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00880594
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine 25 mg/day administered in the evening. Dosing may be increased dependent upon side-effects and clinical response to a maximum of 100 mg/day. Absent significant side-effects, all patients are increased at the one week visit to 50 mg/day at bedtime if they have not achieved a report of Adequate relief. Thereafter, up to week 4, the daily desipramine dose may be increased weekly by 25 mg up to the 100 mg/d maximum.
Study: NCT01960153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
Study: NCT01549977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat placebo-matching tablets
Study: NCT02413047
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
Study: NCT02413047
Drug: 6 mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Study: NCT02413047
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.
Study: NCT02933502
Drug: DSXS topical product
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment daily for 28 days
Study: NCT02020408
Drug: [11C]DASB
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPND of \[11C\]DASB.
Study: NCT02428205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive placebo prior to each EIBI session
Study: NCT00371904
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care
Study: NCT03697681
Drug: 0.9% NaCl (normal saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same amount of normal saline solution without the addition of tranexamic acid is administered in the same manner as the experimental group(Tranexamic acid intervention group).
Study: NCT02980133
Drug: Placebo MDPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo was administered via MDPI per the schedule specified in the arm.
Study: NCT03824587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive Drug
Study: NCT03824587
Drug: Phosphate Binder Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care phosphate binder use at study entry was maintained throughout the entire study
Study: NCT01969032
Drug: Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
Study: NCT00004689
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no